| Patient | Jack London |
|---|---|
| Date of birth | 1987-01-12 |
| Identifiers | MRN HR-ET010-SYN; SSN (made up) 000-10-4482 |
| Document date | 2026-11-01 |
| Author | Eleanor Whitcombe-Ibe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation. Concerns: Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again; He knows the drinking is hurting him and wants to stop without losing his work; He wants to keep writing a thousand words every morning. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake | One tablet by mouth twice a day, self-directed | Oral route | 2024-08-01 to 2026-08-04 | stopped | S |
| Losartan 50 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-08-04 to 2026-09-15 | completed | S |
| Losartan 100 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-09-15 | active | S |
| Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check | Up to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or driving | Oral route | 2026-08-04 to 2026-08-08 | completed | S |
| Thiamine 100 mg oral tablet once daily | One tablet by mouth daily | Oral route | 2026-08-04 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen | One to two tablets by mouth every six hours as needed; no more than four tablets a day | Oral route | 2026-08-04 | active | S |
| Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines | One tablet by mouth every morning | Oral route | 2026-08-18 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily | One tablet by mouth daily | Oral route | 2026-09-15 | active | S |
| Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery | One tablet by mouth every morning; sick-day rules in writing | Oral route | 2026-10-13 | active | S |
| Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicine | Apply 4 g to the ankle four times a day for up to seven days | Topical route | 2026-09-01 to 2026-09-08 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Ultrasound of the abdomen and kidneys: right kidney 10.8 cm and left 11.0 cm with increased cortical echogenicity and preserved cortical thickness, no stones, no hydronephrosis, no cysts; bright liver consistent with steatosis, smooth outline, normal spleen, no ascites | 2026-08-18 to 2026-08-18 | completed | S |
| Vibration-controlled transient elastography of the liver: median liver stiffness 7.2 kPa (interquartile range under 30 percent), controlled attenuation parameter 312 dB/m; advanced fibrosis unlikely | 2026-08-18 to 2026-08-18 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-09-29 to 2026-09-29 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-29 | Influenza vaccine, inactivated, trivalent, preservative-free, for this season | completed | S |
| 2026-09-29 | Pneumococcal conjugate vaccine (PCV20), single dose | completed | S |
| 2026-09-29 | Hepatitis B vaccine (HepB-CpG), first of two doses | completed | S |
| 2026-09-29 | Hepatitis A vaccine, adult, first of two doses | completed | S |
| 2026-10-27 | Hepatitis B vaccine (HepB-CpG), second of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1897 to 1898 | Scurvy in the gold fields in his early twenties; recovered | D (CLM-0003) |
| 1907 to 1909 | Skin sores, swollen and peeling hands and feet, and a silvery skin during a long Pacific voyage, with five weeks in hospital; the hands recovered and the skin cleared without treatment; the diagnoses were never settled | R (CLM-0006, CLM-0007) |
| July 1913 | Appendectomy, at which kidney damage was found | D (CLM-0009) |
| 1914 | Dysentery and joint pain (described as rheumatism) while working abroad | D (CLM-0010) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again | active | S |
| He knows the drinking is hurting him and wants to stop without losing his work | active | S |
| He wants to keep writing a thousand words every morning | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-27; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-10-27; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 2026-10-27; Urea nitrogen [Mass/volume] in Serum or Plasma 24 on 2026-10-27; Creatinine [Mass/volume] in Serum or Plasma 2.13 on 2026-10-27; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-08-04; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 40 on 2026-10-27; Albumin/Creatinine [Mass Ratio] in Urine 96 on 2026-10-27; Urate [Mass/volume] in Serum or Plasma 8.4 on 2026-08-04; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-08-04; Phosphate [Mass/volume] in Serum or Plasma 3.8 on 2026-08-04; Parathyrin.intact [Mass/volume] in Serum or Plasma 74 on 2026-08-04; Hemoglobin [Mass/volume] in Blood 13.6 on 2026-08-04; MCV [Entitic mean volume] in Red Blood Cells by Automated count 96 on 2026-10-27; Platelets [#/volume] in Blood by Automated count 182 on 2026-08-04; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-10-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-10-27; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 54 on 2026-10-27; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-08-04; Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 on 2026-08-04; INR in Platelet poor plasma by Coagulation assay 1 on 2026-08-04; Phosphatidylethanol [Mass/volume] in Blood 6 on 2026-10-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-08-04; Cholesterol [Mass/volume] in Serum or Plasma 214 on 2026-08-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-08-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-08-04; Triglyceride [Mass/volume] in Serum or Plasma 140 on 2026-08-04; Total score [AUDIT] 9 on 2026-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-27; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-10-27; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 24 on 2026-09-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-09-29 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation | resolved | confirmed | R94.4 | S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease. |
| Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney disease | active | confirmed | N18.32 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys. |
| Hypertensive chronic kidney disease, untreated until intake | active | confirmed | I12.9 | S — Synthetic modern diagnosis made at the consultation. |
| Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL | active | confirmed | F10.20 | S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking. |
| Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intake | active | confirmed | K70.0 | S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver. |
| Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place | resolved | confirmed | Z79.1 | S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis. |
| Cigarette smoking, about ten a day; not ready to stop while he stops drinking | active | confirmed | F17.210 | S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim. |
| Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeks | resolved | confirmed | S93.401A | S — Synthetic acute injury; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-04 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-04 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-04 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-08-04 | Urea nitrogen [Mass/volume] in Serum or Plasma | 28 | mg/dL | 7-20 mg/dL | High | S |
| 2026-08-04 | Creatinine [Mass/volume] in Serum or Plasma | 1.98 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-08-04 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 43 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-08-04 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | Below 30 mg/g A1; 30 to 300 A2; above 300 A3 | High | S |
| 2026-08-04 | Urate [Mass/volume] in Serum or Plasma | 8.4 | mg/dL | 4-8 mg/dL | High | S |
| 2026-08-04 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-08-04 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-08-04 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 74 | pg/mL | 15-65 pg/mL | High | S |
| 2026-08-04 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13-17 g/dL | Normal | S |
| 2026-08-04 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 | fL | 80-100 fL | High | S |
| 2026-08-04 | Platelets [#/volume] in Blood by Automated count | 182 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 68 | U/L | 10-40 U/L | High | S |
| 2026-08-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 9-46 U/L | Normal | S |
| 2026-08-04 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 186 | U/L | 8-61 U/L | High | S |
| 2026-08-04 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-08-04 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-08-04 | Phosphatidylethanol [Mass/volume] in Blood | 410 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | High | S |
| 2026-08-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| 2026-08-04 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-08-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-04 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-04 | Total score [AUDIT] | 27 | {score} | S | ||
| 2026-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-08-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 2.04 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 42 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 10-40 U/L | High | S |
| 2026-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 9-46 U/L | Normal | S |
| 2026-08-18 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 8-61 U/L | High | S |
| 2026-09-15 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-15 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-15 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-09-15 | Creatinine [Mass/volume] in Serum or Plasma | 1.96 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-09-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 44 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-09-15 | Albumin/Creatinine [Mass Ratio] in Urine | 128 | mg/g | Below 30 mg/g A1; 30 to 300 A2; above 300 A3 | High | S |
| 2026-09-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 10-40 U/L | Normal | S |
| 2026-09-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 9-46 U/L | Normal | S |
| 2026-09-15 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 82 | U/L | 8-61 U/L | High | S |
| 2026-09-15 | Phosphatidylethanol [Mass/volume] in Blood | 36 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | High | S |
| 2026-09-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-09-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-13 | Potassium [Moles/volume] in Serum or Plasma | 5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.95 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 44 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-10-13 | Phosphatidylethanol [Mass/volume] in Blood | 8 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | Normal | S |
| 2026-10-27 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-27 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-10-27 | Urea nitrogen [Mass/volume] in Serum or Plasma | 24 | mg/dL | 7-20 mg/dL | High | S |
| 2026-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 2.13 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 40 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-10-27 | Albumin/Creatinine [Mass Ratio] in Urine | 96 | mg/g | Below 30 mg/g A1; 30 to 300 A2; above 300 A3 | High | S |
| 2026-10-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 10-40 U/L | Normal | S |
| 2026-10-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 9-46 U/L | Normal | S |
| 2026-10-27 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 54 | U/L | 8-61 U/L | Normal | S |
| 2026-10-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 96 | fL | 80-100 fL | Normal | S |
| 2026-10-27 | Phosphatidylethanol [Mass/volume] in Blood | 6 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | Normal | S |
| 2026-10-27 | Total score [AUDIT] | 9 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-10-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-04 | Body height | 173 | cm | S |
| 2026-08-04 | Body weight | 84.2 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 158 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 92 | /min | S |
| 2026-08-04 | Respiratory rate | 16 | /min | S |
| 2026-08-04 | Body temperature | 36.8 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-18 | Body height | 173 | cm | S |
| 2026-08-18 | Body weight | 83.6 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 84 | /min | S |
| 2026-08-18 | Respiratory rate | 16 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-15 | Body height | 173 | cm | S |
| 2026-09-15 | Body weight | 82.6 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 78 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-13 | Body height | 173 | cm | S |
| 2026-10-13 | Body weight | 81.4 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 72 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-27 | Body height | 173 | cm | S |
| 2026-10-27 | Body weight | 80.9 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 70 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-29 | Body height | 173 | cm | S |
| 2026-09-29 | Body weight | 82 | kg | S |
| 2026-09-29 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 2026-09-29 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-09-29 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-09-29 | Heart rate | 74 | /min | S |
| 2026-09-29 | Respiratory rate | 14 | /min | S |
| 2026-09-29 | Body temperature | 36.6 | Cel | S |
| 2026-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-01 | Body height | 173 | cm | S |
| 2026-09-01 | Body weight | 83.2 | kg | S |
| 2026-09-01 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-09-01 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-09-01 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-09-01 | Heart rate | 88 | /min | S |
| 2026-09-01 | Respiratory rate | 16 | /min | S |
| 2026-09-01 | Body temperature | 36.7 | Cel | S |
| 2026-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-08-04 | Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation | finished | S |
| 2026-08-18 | Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology: kidney staging and cause, ultrasound and elastography, blood pressure target, medicine for alcohol use disorder, and pain relief | finished | S |
| 2026-09-15 | Six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety | finished | S |
| 2026-10-13 | Ten-week review: abstinence, potassium and creatinine after the losartan increase, and the SGLT2 inhibitor | finished | S |
| 2026-10-27 | Twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead | finished | S |
| 2026-09-29 | Periodic adult preventive visit | finished | S |
| 2026-09-01 | Same-day sick visit for a right ankle sprain | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 2021), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readings | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026 | S |
| Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain relief | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 | S |
| Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less salt | completed | GL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-up | completed | GL-APA-AUD-2018, GL-SUD-2021, GL-ASAM-AWM-2020, GL-AASLD-NIT-2025 | S |
| Medicine for alcohol use disorder: naltrexone 50 mg daily, which needs no dose change at his kidney function, with liver tests and a wallet card about opioid blockade; acamprosate not chosen because it needs a lower dose at his creatinine clearance and is avoided below 30 mL/min, and he could not reliably take it three times a day | completed | GL-APA-AUD-2018, GL-SUD-2021, GL-KDIGO-CKD-2024 | S |
| Liver: ultrasound and vibration-controlled transient elastography for an indeterminate FIB-4; abstinence as the treatment | completed | GL-AASLD-ALD-2019, GL-AASLD-NIT-2025 | S |
| SGLT2 inhibitor (dapagliflozin 10 mg daily) once he has been abstinent for some weeks and is eating regularly, because heavy drinking and fasting raise the risk of ketoacidosis; held on days he cannot eat or drink, with potassium and creatinine two to four weeks after starting, accepting an early fall in eGFR | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosing | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-SUICIDE-2024, GL-USPSTF-DEP-2023 | S |
| Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-up | completed | GL-SUD-2021, GL-USPSTF-DEP-2023 | S |
| Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is ready | completed | GL-USPSTF-TOB-2021 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Find out how much kidney function is lost, how long it has been so, and why | 2026-08-18 | completed | Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected | S |
| Stop drinking safely, and stay stopped | 2027-02-02 | active | Withdrawal completed without complications; one evening of drinking at four weeks; abstinent since, with PEth 8 and then 6 ng/mL | S |
| Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80 | 2027-02-02 | active | 158/98 to 122/78 at twelve weeks on losartan 100 mg | S |
| Urine albumin down by at least 30 percent | 2026-10-27 | completed | 240 to 96 mg/g on losartan and then dapagliflozin | S |
| No anti-inflammatory pain medicines, and pain controlled | 2026-10-27 | completed | No naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprain | S |
| Keep the morning writing hours | 2026-10-27 | completed | Wrote every morning through the twelve weeks except the two days of the worst withdrawal | S |
Structured synthetic safety assessment on 2026-08-04: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. Risk factors reviewed without detail: severe alcohol use disorder, a new chronic illness, financial pressure, mild depressive and anxiety symptoms, and firearms on the ranch. He agreed that the rifle and shotgun will be kept locked in the ranch office safe with the ammunition stored apart, and that he will not handle them after drinking. Chlordiazepoxide is dispensed for five days only, with a daily telephone check. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) and the clinic's number were written on a card he carries. Safety is reviewed at every visit [S]